Mineralys presents new lorundrostat data at AHA Hypertension 2026
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive… read more.
